Patents by Inventor Christine Falk

Christine Falk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Attack of tumor cells with missing, low or aberrant MHC expression by combining non MHC-restricted T-cells/NK-cells and MHC-restricted cells
    Patent number: 8142772
    Abstract: This invention is directed to therapeutic compositions containing non-MHC-restricted Tcells/NK-cells in combination with MHC-restricted T-cells and especially to therapeutic compositions, which comprise LAK cells. Furthermore, the present invention is directed to the use of the above combination in the treatment of tumors in humans, which tumors show a missing, low or aberrant expression of MHC class Ia or Ib molecules. By using the aforementioned compositions/combinations it is possible to provide a balanced selective pressure against emergence of tumor cell variants that would otherwise escape immune detection.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: March 27, 2012
    Assignee: Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)
    Inventors: Elfriede Noessner, Elisabeth Weiss, Dolores Schendel, Christine Falk
  • ATTACK OF TUMOR CELLS WITH MISSING, LOW OR ABERRANT MHC EXPRESSION BY COMBINING NON MHC-RESTRICTED T-CELLS/NK-CELLS AND MHC-RESTRICTED CELLS
    Publication number: 20100203086
    Abstract: This invention is directed to therapeutic compositions containing non-MHC-restricted Tcells/NK-cells in combination with MHC-restricted T-cells and especially to therapeutic compositions, which comprise LAK cells. Furthermore, the present invention is directed to the use of the above combination in the treatment of tumors in humans, which tumors show a missing, low or aberrant expression of MHC class Ia or Ib molecules. By using the aforementioned compositions/combinations it is possible to provide a balanced selective pressure against emergence of tumor cell variants that would otherwise escape immune detection.
    Type: Application
    Filed: April 22, 2010
    Publication date: August 12, 2010
    Inventors: Elfriede Noessner, Elisabeth Weiss, Dolores Schendel, Christine Falk
  • Attack of tumor cells with missing, low or aberrant MHC expression by combining non MHC-restricted T-cells/NK-cells and MHC-restricted cells
    Patent number: 7731950
    Abstract: This invention is directed to therapeutic compositions containing non-MHC-restricted T-cells/NK-cells in combination with MHC-restricted T-cells and especially to therapeutic compositions, which comprise LAK cells. Furthermore, the present invention is directed to the use of the above combination in the treatment of tumors in humans, which tumors show a missing, low or aberrant expression of MHC class 1a or 1b molecules. By using the aforementioned compositions/combinations it is possible to provide a balanced selective pressure against emergence of tumor cell variants that would otherwise escape immune detection.
    Type: Grant
    Filed: July 5, 2002
    Date of Patent: June 8, 2010
    Assignee: Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)
    Inventors: Elfriede Noessner, Elisabeth Weiss, Dolores Schendel, Christine Falk
  • Attack of tumor cells with missing, low or aberrant MHC expression by combining non MHC-restricted T-cells/NK-cells and MHC-restricted cells
    Publication number: 20030095955
    Abstract: This invention is directed to therapeutic compositions containing non-MHC-restricted T-cells/NK-cells cells/NK-cells in combination with MHC-restricted T-cells and especially to therapeutic compositions, which comprise LAK cells. Furthermore, the present invention is directed to the use of the above combination in the treatment of tumors in humans, which tumors show a missing, low or aberrant expression of MHC class 1a or 1b molecules. By using the aforementioned compositions/combinations it is possible to provide a balanced selective pressure against emergence of tumor cell variants that would otherwise escape immune detection.
    Type: Application
    Filed: July 5, 2002
    Publication date: May 22, 2003
    Inventors: Elfriede Noessner, Elisabeth Weiss, Dolores Schendel, Christine Falk